Condition (MeSH)
Liver Neoplasms, Experimental
ClinicalTrials.gov lists 1 trial for Liver Neoplasms, Experimental or a narrower condition beneath it. National Cancer Institute (NCI) has the most among industry and government lead sponsors, with 1.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Rows recorded per section (log scale)
3 sections measured, none recorded · 1 not measured yet · 1 not computed
1 of the 1 trial is tagged with Liver Neoplasms, Experimental itself; the rest are tagged with a narrower condition beneath it.
When did Liver Neoplasms, Experimental trials start? (1)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
| Year | Trials started |
|---|---|
| 2011 | 1 |
No forecast is made for this condition: it averages 0.0 trial starts a year over the five years to September, under the 5 a year the method needs.
Recruitment duration, a model prediction: none of the 1 trial evaluated at the 2026-10-09 snapshot is predicted and still running. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Liver Neoplasms, Experimental trials in? (1)
Shown in this order: phase order.
| Phase | Trials |
|---|---|
| Phase 1/2 | 1 |
How many Liver Neoplasms, Experimental trials are recruiting? (1)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Completed | 1 |
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which lead sponsors run the most Liver Neoplasms, Experimental trials? (1)
Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.
| Sponsor | Trials |
|---|---|
| National Cancer Institute (NCI) | 1 |
Which serious adverse events do Liver Neoplasms, Experimental trials report? (10)
Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.
| Adverse event | Subjects affected | Trials |
|---|---|---|
| Rash maculo-papular | 2 | 1 |
| Aspartate aminotransferase increased | 1 | 1 |
| Blood bilirubin increased | 1 | 1 |
| Diarrhea | 1 | 1 |
| Epistaxis | 1 | 1 |
Showing 5 of 10 adverse events.
Which publications cover Liver Neoplasms, Experimental? (80)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| Design, Synthesis and Preclinical Assessment of <sup>99m</sup>Tc-iFAP for In Vivo Fibroblast Activation Protein (FAP) Imaging. | Molecules (Basel, Switzerland) | 2022 | Yes |
| Correlation and Agreement of Yttrium-90 Positron Emission Tomography/Computed Tomography with Ex Vivo Radioembolization Microsphere Deposition in the Rabbit VX2 Liver Tumor Model. | Journal of vascular and interventional radiology : JVIR | 2021 | Yes |
| Liver metastasis restrains immunotherapy efficacy via macrophage-mediated T cell elimination. | Nature medicine | 2021 | Yes |
| Idarubicin-Loaded ONCOZENE Drug-Eluting Bead Chemoembolization in a Rabbit Liver Tumor Model: Investigating Safety, Therapeutic Efficacy, and Effects on Tumor Microenvironment. | Journal of vascular and interventional radiology : JVIR | 2020 | Yes |
| The effect of DC+CIK combined therapy on rat liver cancer model and its modulatory effect on immune functions. | European review for medical and pharmacological sciences | 2018 | Yes |
Showing 5 of 80 publications.
Not on this page
Not measured: delivery record.
Checked, with nothing recorded for this condition: prevalence, rare-disease identity, and sub-conditions in mesh.
Not computed for conditions with fewer than 10 trials: drugs tested.